证券代码：430300 证券简称：辰光医疗 公告编号：2024-094 上海辰光医疗科技股份有限公司 关于公司部分募投项目延期的公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带法律责 任。 上海辰光医疗科技股份有限公司（以下简称"辰光医疗"或"公司"）于 2024 年 12 月 4 日召开第五届董事会第十四次会议、第五届监事会第九次会议， 审议通过《关于公司部分募投项目延期的议案》，同意在募投项目实施主体、募 投资金投资用途及投资规模不发生变更的情况下，根据目前募投项目的实施进 展，拟对部分募投项目进行延期。现将相关情况公告如下： 一、募集资金基本情况 2022 年 12 月 7 日，上海辰光医疗科技股份有限公司发行普通股 15,000,000.00 股，发行方式为向不特定合格投资者公开发行，发行价格为 6.00 元/股，募集资金总额为 90,000,000.00 元，募集资金净额为 72,621,981.14 元，到账时间为 2022 年 11 月 30 日。公司因行使超额配售选择 权取得的募集资金净额为 1 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2024-091 上海辰光医疗科技股份有限公司 持股 5%以上股东减持股份的预披露公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 一、 减持主体的基本情况 | 股东名称 | 股东身份 | | 持股数量（股） | 持股比例 | 当前持股股份来源 | | --- | --- | --- | --- | --- | --- | | 上海天从 企业管理 | 持股 | 5%以 | | | 北京证券交易所上市 | | | | | 6,000,000 | 6.9892% | | | 中心（有限 | 上股东 | | | | 前取得 | | 合伙） | | | | | | 二、 减持计划的主要内容 | 股东名称 | 计划减持 | 计划 减持 | 减持 | | 减持 | | 减持价格 | 拟减持股 | 拟减 持 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 数量（股） | 比 ...

证券代码：430300 证券简称：辰光医疗 公告编号：2024-090 上海辰光医疗科技股份有限公司 股票交易异常波动公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、股票交易异常波动的具体情况 公司股票最近 3 个有成交的交易日（2024 年 11 月 19 日至 2024 年 11 月 21 日）以内收盘价涨幅偏离值累计达到 50.02%，根据《北 京证券交易所交易规则（试行）》的有关规定，属于股票交易异常波 动情形。 二、公司关注并核实的相关情况 (一)关注问题及结论 1、关注问题： （1）前期公告的事项是否取得重大进展或变化，前期披露的公 告是否需要更正、补充； （2）是否存在可能或已经对本公司股票交易价格产生较大影响 的媒体报道或市场传闻，是否涉及热点概念事项； （3）近期公司经营情况及内外部经营环境是否或预计将要发生 重大变化； （4）公司、控股股东和实际控制人是否存在关于本公司的应披 露而未披露的重大事项，或处于筹划阶段的重大事项； （5）是否存在其他可能对股价产生较大影响的重大事 ...

| | 2024-11-21 公告日期 无 | 异常期间 | | | | | --- | --- | --- | --- | --- | --- | | | 辰光医疗(430300) 连续竞价 | 成交数量 （股） | 8815387 | 成交金额（万 元） | 16079.14 | | | 涉及事项 当日收盘价涨幅达到20%的前5只股票 | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | 卖出金额（元） | | 买1 | 兴业证券股份有限公司上海分公司 | | | 5789102 | 0 | | 买2 | 东亚前海证券有限责任公司上海分公司 | | | 5543905.7 | 0 | | 买3 | 上海证券有限责任公司宁波北仑新大路证券营业部 | | | 5187144.67 | 5040 | | 买4 | 广发证券股份有限公司广州天河路营业部 | | | 4441104.4 | 32743.16 | | 买5 | 平安证券股份有限公司上海分公司 | | | 4054526.48 | 352989.93 | | 卖1 | 海通证券股份有限公司上海青浦区汇金路营业部 | ...

| | 2024-11-21 公告日期 异常期间 | | 2024-11-21 | | | | --- | --- | --- | --- | --- | --- | | | 辰光医疗(430300) 连续竞价 （股） | 成交数量 | 34341881.0 | 成交金额（万 元） | 51694.43 | | | 北交所股票最近3个有成交的交易日以内收盘价涨跌幅偏离值累计达到+40% 涉及事项 | | | | | | | (-40%) | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | 卖出金额（元） | | 买1 | 国信证券股份有限公司深圳互联网分公司 | | | 10088253.63 | 7147166.07 | | 买2 | 中信建投证券股份有限公司广州珠江新城证券营业部 | | | 9245912.1 | 7245966.36 | | 买3 | 银泰证券有限责任公司淄博华光路证券营业部 | | | 9034556.73 | 8511795.87 | | 买4 | 上海证券有限责任公司宁波北仑新大路证券营业部 | | | 7132827.24 | 189939 ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 异常期间涨跌幅偏离值累计 | 2024-11- | 驰诚股份 | 834407 | 12758074.0 | 31120.99 | 21 | 达到64.42% | | 异常期间涨跌幅偏离值累计 | 2024-11- | 汉维科技 | 836957 | 18560515.0 | 31327.14 | 21 | 达到64.38% | | 异常期间涨跌幅偏离值累计 | 2024-11- | 辰光医疗 | 430300 | 34341881.0 | 51694.43 | 21 | 达到50.02% | | 异常期间涨跌幅偏离值累计 | 2024-11- | 迪尔化工 | 831304 | 59186787.0 | 102393.94 | 21 | 达到48.44% | | 2024-11- | 当日收盘价涨幅达到29.99% | 汉维科技 | 836957 | 11906412.0 | 21939.34 | 21 | ...

| | 公告日期 | 2024-11-19 异常期间 | 无 | | | | --- | --- | --- | --- | --- | --- | | | 辰光医疗(430300) 13523579.0 | 成交数量 连续竞价 | | 成交金额（万 | 18449.41 | | | | （股） | | 元） | | | | 涉及事项 当日价格振幅达到30%的前5只股票 | | | | | | 买/卖 | 营业部或交易单元名称 | | | 买入金额（元） | 卖出金额（元） | | 买1 | 银泰证券有限责任公司淄博华光路证券营业部 | | | 9034556.73 | 0 | | 买2 | 国盛证券有限责任公司鹰潭胜利西路营业部 | | | 3969803.68 | 10179327.64 | | 买3 | 中信建投证券股份有限公司厦门杏东路证券营业部 | | | 3774266.34 | 740327.47 | | 买4 | 国信证券股份有限公司深圳互联网分公司 | | | 3288555.67 | 2535879.66 | | 买5 | 东方财富证券股份有限公司昌都两江大道证券营业部 | | | 313 ...

| 日期 | 代码 | 简称 | 成交数量（股） | 成交金额（万元） | 披露原因 | | --- | --- | --- | --- | --- | --- | | 2024-11- | 831832 | 科达自控 | 18527801.0 | 59152.52 | 当日收盘价涨幅达到29.99% | | 19 | | | | | | | 2024-11- | 873152 | 天宏锂电 | 24108513.0 | 42401.59 | 当日收盘价涨幅达到29.95% | | 19 | | | | | | | 2024-11- | 832000 | 安徽凤凰 | 13114329.0 | 34373.51 | 当日收盘价涨幅达到24.91% | | 19 | | | | | | | 2024-11- | 830799 | 艾融软件 | 18671901.0 | 118899.97 | 当日收盘价涨幅达到21.66% | | 19 | | | | | | | 2024-11- | 873152 | 天宏锂电 | 24108513.0 | 42401.59 | 当日价格振幅达到48.76% | | 19 | ...

Financial Performance - Net profit attributable to shareholders for the first nine months of 2024 was CNY -15,875,336.84, a decline of 129.77% compared to CNY -6,909,240.17 in the same period of 2023[3] - Operating revenue for the first nine months of 2024 decreased by 13.44% to CNY 86,106,323.16 from CNY 99,477,600.49 in the previous year[3] - The gross profit margin decreased significantly, leading to an operating loss of CNY -20,154,975.53, a decline of 71.89% compared to the previous year[5] - Operating profit for the first nine months of 2024 was -¥20,154,975.53, compared to -¥11,725,775.26 in the same period of 2023, indicating a worsening performance[27] - Net profit for the first nine months of 2024 was -¥15,875,336.84, compared to -¥6,909,240.17 in the same period of 2023, reflecting a significant increase in losses[27] - Total operating revenue for the first nine months of 2024 was ¥86,106,323.16, a decrease of 13.5% compared to ¥99,477,600.49 in the same period of 2023[26] Cash Flow - The company's cash flow from operating activities showed a net outflow of CNY -44,860,789.66, a significant decline of 99.01% compared to CNY -22,542,387.28 in the same period last year[3] - Operating cash inflow for the first nine months of 2024 was CNY 102,200,723.94, a decrease of 15.9% compared to CNY 121,614,958.73 in the same period of 2023[31] - Net cash outflow from operating activities was CNY -44,860,789.66, worsening from CNY -22,542,387.28 year-over-year[32] - Total cash outflow from investing activities was CNY 93,344,285.86, significantly higher than CNY 44,741,731.67 in the previous year[32] - Net cash flow from financing activities increased to CNY 31,653,383.58, compared to CNY 25,943,766.67 in the same period last year[32] Assets and Liabilities - Total assets as of September 30, 2024, amounted to CNY 497,634,890.51, representing a 2.87% increase from CNY 483,752,548.96 at the end of 2023[3] - Current liabilities rose to ¥177.88 billion, up from ¥146.89 billion, indicating an increase of about 21.1%[21] - Total liabilities increased to ¥224.53 billion from ¥194.77 billion, reflecting a growth of about 15.3%[22] - The total equity attributable to shareholders decreased to ¥278.77 billion from ¥289.85 billion, a decline of approximately 3.8%[25] Shareholder Information - The total number of ordinary shares at the end of the reporting period is 85,847,126, with 70.00% being unrestricted shares and 30.00% being restricted shares[8] - The largest shareholder, Wang Jie, holds 23,365,988 shares, representing 27.22% of the total shares[9] - The number of ordinary shareholders is 2,613 at the end of the reporting period[8] Research and Development - Research and development expenses increased by 51.05% to CNY 17,729,835.43, indicating a focus on ongoing projects despite a slight overall decrease in total R&D investment[4] - Research and development expenses rose to ¥17,729,835.43, an increase of 51.1% from ¥11,738,080.02 in the same period of 2023[26] Guarantees and Commitments - The company provided a guarantee of 10 million yuan for its subsidiary, with a guarantee balance of 10 million yuan, which is 50% of the net assets[14][15] - The company provided a total of 90 million yuan in guarantees for loans, with a remaining balance of 53.8 million yuan as of September 30, 2024[16] - The company has signed a maximum guarantee contract with China Construction Bank for 90 million yuan, with a cumulative loan balance of 53.8 million yuan as of September 30, 2024[18] Other Financial Metrics - Non-recurring gains and losses totaled CNY 4,986,253.46 after tax, contributing positively to the overall financial results despite operational losses[6] - The company’s weighted average return on equity based on net profit attributable to shareholders was -5.65%, down from -2.29% in the previous year[3] - Basic and diluted earnings per share for the first nine months of 2024 were both -¥0.18, compared to -¥0.08 in the same period of 2023[28]

证券代码：430300 证券简称：辰光医疗 公告编号：2024-087 上海辰光医疗科技股份有限公司 第五届董事会第十三次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担个别及连带法律责任。 一、会议召开和出席情况 （一）会议召开情况 3.会议召开方式：现场 会议的召集、召开和表决程序符合有关法律法规、规范性文件和 和《公司章程》的规定。 1.会议召开时间：2024 年 10 月 28 日 上午 9 时 2.会议召开地点：上海辰光医疗科技股份有限公司 三楼会议室 4.发出董事会会议通知的时间和方式：会议通知于 2024 年 10 月 22 日以书面和电话形式送达各位董事。 5.会议主持人：董事长 王杰先生 6.会议列席人员：监事、高级管理人员列席。 7.召开情况合法、合规、合章程性说明： 二、议案审议情况 （一）审议通过《2024 年第三季度报告》 1.议案内容： 根据有关法律法规、规范性文件及《公司章程》规定，结合公司 2024 年第三季度的经营情况，公司编制了《2024 年第三季度报告》。 该议案具体内容详 ...